<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01782131</url>
  </required_header>
  <id_info>
    <org_study_id>P06200</org_study_id>
    <secondary_id>2011-003938-14</secondary_id>
    <secondary_id>5592-069</secondary_id>
    <nct_id>NCT01782131</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069)</brief_title>
  <official_title>A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of posaconazole (POS) versus&#xD;
      voriconazole (VOR) in the treatment of adults and adolescents with invasive aspergillosis&#xD;
      (IA). The primary hypothesis is that the all-cause mortality through Day 42 in the POS&#xD;
      treatment group is non-inferior to that in the VOR treatment group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 25, 2013</start_date>
  <completion_date type="Actual">September 10, 2019</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population</measure>
    <time_frame>Up to ~42 days</time_frame>
    <description>The percentage of participants who died with posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) in the Intention to Treat (ITT) population through Day 42 was assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population</measure>
    <time_frame>Up to ~42 days</time_frame>
    <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the Full Analysis Set (FAS) population through Day 42 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died Through Day 84 in the ITT Population</measure>
    <time_frame>Up to ~84 days</time_frame>
    <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the ITT population through Day 84 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Died Through Day 84 in the FAS Population</measure>
    <time_frame>Up to ~ 84 days</time_frame>
    <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the FAS population through Day 84 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population</measure>
    <time_frame>Up to 12 weeks (± 4 weeks)</time_frame>
    <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 12 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population</measure>
    <time_frame>Up to 6 weeks (± 2 weeks)</time_frame>
    <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 6 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>The number of participants experiencing mortality at Day 42, Day 84 and Day 114 in participants with proven or probable IA receiving POS versus VOR were assessed. The Kaplan-Meier estimate reports the number of participants who experienced death (all causes) through Day 114 or ~16 weeks. Participants who did not have any endpoint event until last visit or who were lost to follow-up and had no event were censored at the time of last available information (last study visit). For Day 42 and Day 84, missing or 'unable to determine' responses were considered as failures (dead).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>The number of participants who died due to IA receiving POS versus VOR through Day 42 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population</measure>
    <time_frame>Up to 84 days</time_frame>
    <description>The number of participants who died due to IA receiving POS versus VOR in the FAS population through Day 84 was assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Tier 1 Treatment Emergent Adverse Events</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>The percentage of participants with Tier 1 treatment-emergent adverse events (TEAEs) was determined. The Tier 1 TEAEs included hepatic safety (elevated aspartate serum transaminase [AST] or alanine serum transaminase [ALT] value ≥3x upper limit of normal (ULN) and an elevated total bilirubin value ≥2x ULN and, at the same time, an alkaline phosphatase value &lt;2 ULN); central nervous system (CNS) and visual disturbances (eye disorders, nervous system disorders, psychiatric disorders), dermatologic reactions, and adrenal insufficiency or temporally associated TEAEs of hypotension.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Adverse Event</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Drug Related Adverse Event</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Serious Adverse Event</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>A serious adverse event (SAE) was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With at Least One Serious Drug Related Adverse Event</measure>
    <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
    <description>An SAE was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</measure>
    <time_frame>Up to ~12 weeks</time_frame>
    <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady State Average Concentration (Cavg) of Posaconazole With Food Intake</measure>
    <time_frame>Baseline, and at pre-dose on Day 7, Week 2, Week 4, Week 6, and Week 12</time_frame>
    <description>The characterization of the pharmacokinetics (PK) parameters of POS was determined from plasma samples taken at steady-state after receiving oral tablet of POS. Steady-state Cavg, where Cavg is defined as area under the concentration time-curve from 0 to 24 hours (AUC0-24hr) divided by the dosing interval. Data is presented in POS group column only. No evaluation of food intake on the VOR capsule was presented.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">585</enrollment>
  <condition>Fungal Infections</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>Posaconazole (POS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Voriconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Posaconazole</intervention_name>
    <description>POS IV: Day 1: 300 mg BID Day 2-84: 300 mg QD POS oral: Day 1: 300 mg BID Day 2-84: 300 mg QD</description>
    <arm_group_label>Posaconazole (POS)</arm_group_label>
    <other_name>SCH 056592</other_name>
    <other_name>MK-5592</other_name>
    <other_name>Noxafil®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Voriconazole</intervention_name>
    <description>VOR IV: Day 1: 6 mg/kg per body weight administered BID Day 2-84: 4 mg/kg per body weight administered BID VOR oral: Day 1: 300 mg BID Day 2-84: 200 mg BID</description>
    <arm_group_label>Voriconazole</arm_group_label>
    <other_name>VFEND®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo received for Posaconazole (IV and oral) or Voriconazole (oral)</description>
    <arm_group_label>Posaconazole (POS)</arm_group_label>
    <arm_group_label>Voriconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Weight &gt;40 kg (88 lb) and ≤150 kg (330 lb); if between 13 and 14 years of age must&#xD;
             weigh &gt;= 50 kg (110 lb)&#xD;
&#xD;
          -  Must meet the criteria for proven, probable, or possible IA as per 2008 European&#xD;
             Organization for Research and Treatment of Cancer/Invasive Fungal Infections&#xD;
             Cooperative Group and the National Institute of Allergy and Infectious Diseases&#xD;
             Mycoses Study Group (EORTC/MSG) disease definitions at the time of randomization.&#xD;
             Proven IA will include those participants with the demonstration of fungal elements&#xD;
             (by cytology, microscopy, or culture) in diseased tissue (sterile sampling). Probable&#xD;
             IA includes participants with at least 1 host factor, clinical criteria, as well as&#xD;
             mycological criteria including both direct and indirect methods. Possible IA includes&#xD;
             participants with at least 1 host factor and clinical criteria but without mycological&#xD;
             criteria. A modification to the 2008 EORTC/MSG criteria regarding risk factors has&#xD;
             been made to allow for the inclusion of participants with any duration of neutropenia&#xD;
             as an acceptable inclusion host factor.&#xD;
&#xD;
          -  If with possible IA at time of randomization must be willing or be in process of an&#xD;
             ongoing diagnostic work up which is anticipated to result in a mycological diagnosis&#xD;
             of proven or probable IA postrandomization.&#xD;
&#xD;
          -  Must have a central line (e.g., central venous catheter, peripherally-inserted central&#xD;
             catheter, etc.) in place or planned to be in place prior to beginning IV study&#xD;
             therapy. If without central catheter access, must be clinically stable and able to&#xD;
             receive oral study therapy.&#xD;
&#xD;
          -  Acute IA defined as duration of clinical syndrome of &lt;30 days.&#xD;
&#xD;
          -  Must be willing to adhere to dosing, study visit schedule, and mandatory procedures as&#xD;
             outlined in the protocol. The participant must be willing to continue on study therapy&#xD;
             for up to 12 weeks and remain in the study through the 1-month follow-up visit.&#xD;
&#xD;
          -  The participant must have the ability to transition to oral study therapy during the&#xD;
             course of the study.&#xD;
&#xD;
          -  Female participants of child-bearing potential must be using a medically accepted&#xD;
             method of birth control before beginning study-drug treatment and agree to continue&#xD;
             its use for 30 days after stopping study medication&#xD;
&#xD;
          -  Is not taking prohibited antifungal prophylaxis or treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic (&gt;1 month duration) IA, relapsed/recurrent IA, or refractory IA which has not&#xD;
             responded to antifungal therapy.&#xD;
&#xD;
          -  Has pulmonary sarcoidosis, aspergilloma, or allergic bronchopulmonary aspergillosis&#xD;
             (ABPA).&#xD;
&#xD;
          -  Known mixed invasive mold fungal infection including Zygomycetes, and/or a known&#xD;
             invasive Aspergillus fungal infection in which either study drug may not be considered&#xD;
             active.&#xD;
&#xD;
          -  Receipt of any systemic (oral, intravenous, or inhaled) antifungal therapy for this&#xD;
             infection episode for 4 or more consecutive days (&gt;= 96 hours) immediately before&#xD;
             randomization.&#xD;
&#xD;
          -  Developed the current episode of IA infection during receipt of &gt;13 days of antifungal&#xD;
             prophylaxis with an agent considered to be a mold-active antifungal agent.&#xD;
&#xD;
          -  Receipt of posaconazole or voriconazole as empirical treatment for this infection for&#xD;
             4 days (96 hours) or more within the 15 days immediately before randomization.&#xD;
&#xD;
          -  Has condition that, in the opinion of the investigator, may interfere with optimal&#xD;
             participation in the study.&#xD;
&#xD;
          -  Known hypersensitivity or other serious adverse reaction to any azole antifungal&#xD;
             therapy or to any other ingredient of the study medication used.&#xD;
&#xD;
          -  Females who are pregnant, intend to become pregnant, or are nursing at the time of&#xD;
             randomization.&#xD;
&#xD;
          -  Known history of Torsade de Pointes, unstable cardiac arrhythmia or proarrhythmic&#xD;
             conditions, or a history of recent myocardial infarction within 90 days of study&#xD;
             entry.&#xD;
&#xD;
          -  Has significant liver dysfunction&#xD;
&#xD;
          -  Hepatic cirrhosis or a Child-Pugh score of C (severe hepatic impairment) at the time&#xD;
             of randomization.&#xD;
&#xD;
          -  Severe renal insufficiency (estimated creatinine clearance &lt;20 mL/min) or on&#xD;
             hemodialysis at the time of randomization or likely to require dialysis during the&#xD;
             study.&#xD;
&#xD;
          -  Known hereditary problem of galactose intolerance, Lapp lactase deficiency, or&#xD;
             glucose-galactose malabsorption.&#xD;
&#xD;
          -  Acute symptomatic pancreatitis within 6 months of study entry or a diagnosis of&#xD;
             chronic pancreatitis at the time of randomization.&#xD;
&#xD;
          -  Active skin lesion consistent with squamous cell carcinoma at the time of&#xD;
             randomization, or a current or prior history of malignant melanoma within 5 years of&#xD;
             study entry.&#xD;
&#xD;
          -  On artificial ventilation or receiving acute Continuous Positive Airway Pressure&#xD;
             (CPAP)/Bilevel Positive Airway Pressure (BPAP) at the time of randomization.&#xD;
&#xD;
          -  Known or suspected Gilbert's disease at the time of randomization.&#xD;
&#xD;
          -  Requires treatment with other medications that cannot be stopped and for which there&#xD;
             is a known contraindication to co-administration of one or more of the study drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Colombia</country>
    <country>Croatia</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 30, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <results_first_submitted>July 16, 2020</results_first_submitted>
  <results_first_submitted_qc>August 6, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 21, 2020</results_first_posted>
  <disposition_first_submitted>June 15, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 15, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 17, 2020</disposition_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voriconazole</mesh_term>
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 7, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/31/NCT01782131/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>After a screening phase of up to 7 days, 585 participants were enrolled/randomized, but only 575 began treatment (288 in the posaconazole [POS] group and 287 in the voriconazole [VOR] group).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Posaconazole</title>
          <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
        <group group_id="P2">
          <title>Voriconazole</title>
          <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="288"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="184"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not provided</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population included all participants who received at least one dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Posaconazole</title>
          <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
        <group group_id="B2">
          <title>Voriconazole</title>
          <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="288"/>
            <count group_id="B2" value="287"/>
            <count group_id="B3" value="575"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.5" spread="16.7"/>
                    <measurement group_id="B2" value="53.0" spread="15.9"/>
                    <measurement group_id="B3" value="53.3" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="231"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="220"/>
                    <measurement group_id="B2" value="219"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="194"/>
                    <measurement group_id="B2" value="192"/>
                    <measurement group_id="B3" value="386"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population</title>
        <description>The percentage of participants who died with posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) in the Intention to Treat (ITT) population through Day 42 was assessed.</description>
        <time_frame>Up to ~42 days</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population</title>
          <description>The percentage of participants who died with posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) in the Intention to Treat (ITT) population through Day 42 was assessed.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.3"/>
                    <measurement group_id="O2" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme. The p-Value is based on the one-sided non-inferiority test. Non-inferiority of posaconazole vs. voriconazole is established if the upper limit of the 95% confidence interval is less than 10%.</non_inferiority_desc>
            <p_value>&lt;.0001</p_value>
            <method>Miettinen and Nurminen</method>
            <param_type>Estimated Difference in Percent</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population</title>
        <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the Full Analysis Set (FAS) population through Day 42 was assessed.</description>
        <time_frame>Up to ~42 days</time_frame>
        <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population</title>
          <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the Full Analysis Set (FAS) population through Day 42 was assessed.</description>
          <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme.</non_inferiority_desc>
            <param_type>Estimated Difference in Percent</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>8.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died Through Day 84 in the ITT Population</title>
        <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the ITT population through Day 84 was assessed.</description>
        <time_frame>Up to ~84 days</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died Through Day 84 in the ITT Population</title>
          <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the ITT population through Day 84 was assessed.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1"/>
                    <measurement group_id="O2" value="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme.</non_inferiority_desc>
            <param_type>Estimated Difference in Percent</param_type>
            <param_value>-2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.9</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Died Through Day 84 in the FAS Population</title>
        <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the FAS population through Day 84 was assessed.</description>
        <time_frame>Up to ~ 84 days</time_frame>
        <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Died Through Day 84 in the FAS Population</title>
          <description>The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the FAS population through Day 84 was assessed.</description>
          <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.4"/>
                    <measurement group_id="O2" value="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme.</non_inferiority_desc>
            <param_type>Estimated Difference in Percent</param_type>
            <param_value>3.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>13.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population</title>
        <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 12 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
        <time_frame>Up to 12 weeks (± 4 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population</title>
          <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 12 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
          <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3"/>
                    <measurement group_id="O2" value="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme.</non_inferiority_desc>
            <param_type>Estimated Difference in Percent</param_type>
            <param_value>-3.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.9</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population</title>
        <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 6 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
        <time_frame>Up to 6 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population</title>
          <description>The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 6 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.</description>
          <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method stratified by the risk for mortality/poor outcome (high risk, not high risk) and using Cochran-Mantel-Haenszel weighting scheme.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>10.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)</title>
        <description>The number of participants experiencing mortality at Day 42, Day 84 and Day 114 in participants with proven or probable IA receiving POS versus VOR were assessed. The Kaplan-Meier estimate reports the number of participants who experienced death (all causes) through Day 114 or ~16 weeks. Participants who did not have any endpoint event until last visit or who were lost to follow-up and had no event were censored at the time of last available information (last study visit). For Day 42 and Day 84, missing or 'unable to determine' responses were considered as failures (dead).</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)</title>
          <description>The number of participants experiencing mortality at Day 42, Day 84 and Day 114 in participants with proven or probable IA receiving POS versus VOR were assessed. The Kaplan-Meier estimate reports the number of participants who experienced death (all causes) through Day 114 or ~16 weeks. Participants who did not have any endpoint event until last visit or who were lost to follow-up and had no event were censored at the time of last available information (last study visit). For Day 42 and Day 84, missing or 'unable to determine' responses were considered as failures (dead).</description>
          <population>The analysis population consisted of all randomized participants who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions) and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 42 (missing responses were included as dead)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 84 (missing responses were included as dead)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 114</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of Time to All-Cause Mortality Through Day 114: Posaconazole vs. Voriconazole</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2767</p_value>
            <p_value_desc>Based on Stratified Log-Rank method stratified by the risk for mortality/poor outcome (high risk, not high risk).</p_value_desc>
            <method>Kaplan-Meier</method>
            <method_desc>From product-limit (Kaplan-Meier) method for censored data.</method_desc>
            <param_type>Survival Rate in Percent</param_type>
            <param_value>60.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>52.8</ci_lower_limit>
            <ci_upper_limit>67.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population</title>
        <description>The number of participants who died due to IA receiving POS versus VOR through Day 42 was assessed.</description>
        <time_frame>Up to 42 days</time_frame>
        <population>All randomized participants who died by Day 42 and who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions), and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population</title>
          <description>The number of participants who died due to IA receiving POS versus VOR through Day 42 was assessed.</description>
          <population>All randomized participants who died by Day 42 and who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions), and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>20.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1</ci_lower_limit>
            <ci_upper_limit>42.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population</title>
        <description>The number of participants who died due to IA receiving POS versus VOR in the FAS population through Day 84 was assessed.</description>
        <time_frame>Up to 84 days</time_frame>
        <population>All randomized participants who died by Day 84 and who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions), and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population</title>
          <description>The number of participants who died due to IA receiving POS versus VOR in the FAS population through Day 84 was assessed.</description>
          <population>All randomized participants who died by Day 84 and who have been classified as having proven or probable IA (based upon independent adjudication assessment using the modified 2008 European Organization for Research and Treatment of Cancer/Mycoses study group [EORTC/MSG] definitions), and received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen and Nurminen's method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>11.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.9</ci_lower_limit>
            <ci_upper_limit>28.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Tier 1 Treatment Emergent Adverse Events</title>
        <description>The percentage of participants with Tier 1 treatment-emergent adverse events (TEAEs) was determined. The Tier 1 TEAEs included hepatic safety (elevated aspartate serum transaminase [AST] or alanine serum transaminase [ALT] value ≥3x upper limit of normal (ULN) and an elevated total bilirubin value ≥2x ULN and, at the same time, an alkaline phosphatase value &lt;2 ULN); central nervous system (CNS) and visual disturbances (eye disorders, nervous system disorders, psychiatric disorders), dermatologic reactions, and adrenal insufficiency or temporally associated TEAEs of hypotension.</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Tier 1 Treatment Emergent Adverse Events</title>
          <description>The percentage of participants with Tier 1 treatment-emergent adverse events (TEAEs) was determined. The Tier 1 TEAEs included hepatic safety (elevated aspartate serum transaminase [AST] or alanine serum transaminase [ALT] value ≥3x upper limit of normal (ULN) and an elevated total bilirubin value ≥2x ULN and, at the same time, an alkaline phosphatase value &lt;2 ULN); central nervous system (CNS) and visual disturbances (eye disorders, nervous system disorders, psychiatric disorders), dermatologic reactions, and adrenal insufficiency or temporally associated TEAEs of hypotension.</description>
          <population>The analysis population consisted of all participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abnormal Hepatic Laboratory Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CNS and Visual Disturbances</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dermatologic Reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.3"/>
                    <measurement group_id="O2" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Adrenal Insufficiency or Temporal Hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Abnormal Hepatic Laboratory Value</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8305</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percent</param_type>
            <param_value>0.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>3.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CNS and Visual Disturbances</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3633</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-3.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Dermatologic Reactions</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3724</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percent</param_type>
            <param_value>-2.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Adrenal Insufficiency or Temporal Hypotension</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6431</p_value>
            <method>Miettinen &amp; Nurminen</method>
            <param_type>Difference in Percent</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Adverse Event</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Adverse Event</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>0.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.8</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Drug Related Adverse Event</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Drug Related Adverse Event</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9"/>
                    <measurement group_id="O2" value="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-10.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.9</ci_lower_limit>
            <ci_upper_limit>-2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Serious Adverse Event</title>
        <description>A serious adverse event (SAE) was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Serious Adverse Event</title>
          <description>A serious adverse event (SAE) was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.8"/>
                    <measurement group_id="O2" value="59.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.1</ci_lower_limit>
            <ci_upper_limit>9.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With at Least One Serious Drug Related Adverse Event</title>
        <description>An SAE was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
        <time_frame>Up to ~16 weeks (± 2 weeks)</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With at Least One Serious Drug Related Adverse Event</title>
          <description>An SAE was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6"/>
                    <measurement group_id="O2" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.6</ci_lower_limit>
            <ci_upper_limit>2.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
        <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
        <time_frame>Up to ~12 weeks</time_frame>
        <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
          <group group_id="O2">
            <title>Voriconazole</title>
            <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event</title>
          <description>An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.</description>
          <population>The analysis population consisted of all randomized participants who received at least one dose of study treatment.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="35.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Based on Miettinen &amp; Nurminen method.</non_inferiority_desc>
            <param_type>Difference in Percent</param_type>
            <param_value>-3.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.0</ci_lower_limit>
            <ci_upper_limit>4.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Steady State Average Concentration (Cavg) of Posaconazole With Food Intake</title>
        <description>The characterization of the pharmacokinetics (PK) parameters of POS was determined from plasma samples taken at steady-state after receiving oral tablet of POS. Steady-state Cavg, where Cavg is defined as area under the concentration time-curve from 0 to 24 hours (AUC0-24hr) divided by the dosing interval. Data is presented in POS group column only. No evaluation of food intake on the VOR capsule was presented.</description>
        <time_frame>Baseline, and at pre-dose on Day 7, Week 2, Week 4, Week 6, and Week 12</time_frame>
        <population>The analysis population consisted of all randomized participants in the POS group only who received at least one dose of study treatment. Per protocol, the VOR group was not included in the analysis population because the food intake evaluation was limited to the POS group.</population>
        <group_list>
          <group group_id="O1">
            <title>Posaconazole</title>
            <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
          </group>
        </group_list>
        <measure>
          <title>Steady State Average Concentration (Cavg) of Posaconazole With Food Intake</title>
          <description>The characterization of the pharmacokinetics (PK) parameters of POS was determined from plasma samples taken at steady-state after receiving oral tablet of POS. Steady-state Cavg, where Cavg is defined as area under the concentration time-curve from 0 to 24 hours (AUC0-24hr) divided by the dosing interval. Data is presented in POS group column only. No evaluation of food intake on the VOR capsule was presented.</description>
          <population>The analysis population consisted of all randomized participants in the POS group only who received at least one dose of study treatment. Per protocol, the VOR group was not included in the analysis population because the food intake evaluation was limited to the POS group.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="58"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1625" spread="902.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1992" spread="1190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1994" spread="956.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2005" spread="1333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2169" spread="1255"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to ~Week 16 (± 2 weeks)</time_frame>
      <desc>The analysis population was defined as all randomized participants who received at least one dose of study treatment. The analysis population for the all-cause mortality included all randomized participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>Posaconazole</title>
          <description>Participants received 300 mg posaconazole (POS) intravenous (IV) twice per day (BID) on Day 1, and then received 300 mg POS IV plus placebo IV once per day (QD) starting on Day 2 until clinically stable when participants transitioned to oral POS tablets plus oral placebo tablets QD for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
        <group group_id="E2">
          <title>Voriconazole</title>
          <description>Participants received 6 mg/kg voriconazole (VOR) IV twice per day (BID) on Day 1, and then received 4 mg/kg VOR IV BID on Day 2 until clinically stable when participants transitioned to oral therapy with VOR capsules or VOR placebo capsules BID for up to 12 weeks of treatment. Most participants were expected to initiate treatment with IV therapy and transition to oral therapy as clinically indicated, with some participants initiating treatment with oral therapy, per clinical judgment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="99" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="178" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="32" subjects_affected="24" subjects_at_risk="288"/>
                <counts group_id="E2" events="26" subjects_affected="21" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Thrombotic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Accessory cardiac pathway</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastric varices haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neutropenic colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hydrocholecystis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Acute graft versus host disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute graft versus host disease in skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in gastrointestinal tract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Graft versus host disease in liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Haemophagocytic lymphohistiocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Kidney transplant rejection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Anal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bacterial pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Brain abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="288"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cellulitis pharyngeal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cerebral aspergillosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Citrobacter sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Corona virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cystitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus viraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Disseminated cytomegaloviral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Emphysematous cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enterobacter pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enterobacter sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enterococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Enterococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Escherichia bacteraemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatosplenic candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Mucormycosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Muscle abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Nocardiosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia pseudomonal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pseudomonal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary mycosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Relapsing fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Renal graft infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sepsis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="288"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Urinary tract infection enterococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus test positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tumour lysis syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="288"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>B-cell type acute leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blast crisis in myelogenous leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Leukaemia recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour of the lung</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Precursor T-lymphoblastic lymphoma/leukaemia refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Primary mediastinal large B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Tumour associated fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cerebral disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Wernicke's encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="288"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary alveolar haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="288"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="288"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis exfoliative generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="288"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="232" subjects_at_risk="288"/>
                <counts group_id="E2" subjects_affected="225" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="23" subjects_at_risk="288"/>
                <counts group_id="E2" events="46" subjects_affected="29" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="21" subjects_at_risk="288"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" events="23" subjects_affected="17" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="288"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="27" subjects_at_risk="288"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="36" subjects_affected="32" subjects_at_risk="288"/>
                <counts group_id="E2" events="26" subjects_affected="23" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="66" subjects_affected="52" subjects_at_risk="288"/>
                <counts group_id="E2" events="57" subjects_affected="50" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="83" subjects_affected="65" subjects_at_risk="288"/>
                <counts group_id="E2" events="63" subjects_affected="50" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="64" subjects_affected="52" subjects_at_risk="288"/>
                <counts group_id="E2" events="57" subjects_affected="38" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="288"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="288"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="35" subjects_affected="32" subjects_at_risk="288"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="122" subjects_affected="75" subjects_at_risk="288"/>
                <counts group_id="E2" events="127" subjects_affected="69" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cytomegalovirus infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="288"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="49" subjects_affected="39" subjects_at_risk="288"/>
                <counts group_id="E2" events="46" subjects_affected="34" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="46" subjects_affected="36" subjects_at_risk="288"/>
                <counts group_id="E2" events="41" subjects_affected="34" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="288"/>
                <counts group_id="E2" events="33" subjects_affected="28" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="38" subjects_affected="24" subjects_at_risk="288"/>
                <counts group_id="E2" events="24" subjects_affected="20" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" events="20" subjects_affected="17" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="288"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" events="18" subjects_affected="11" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="288"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="15" subjects_at_risk="288"/>
                <counts group_id="E2" events="27" subjects_affected="13" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="133" subjects_affected="78" subjects_at_risk="288"/>
                <counts group_id="E2" events="72" subjects_affected="49" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="29" subjects_at_risk="288"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="288"/>
                <counts group_id="E2" events="26" subjects_affected="19" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="288"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="288"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="288"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="45" subjects_affected="34" subjects_at_risk="288"/>
                <counts group_id="E2" events="29" subjects_affected="24" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="288"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="288"/>
                <counts group_id="E2" events="17" subjects_affected="16" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="32" subjects_affected="30" subjects_at_risk="288"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="27" subjects_at_risk="288"/>
                <counts group_id="E2" events="28" subjects_affected="24" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="288"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="288"/>
                <counts group_id="E2" events="32" subjects_affected="22" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="33" subjects_affected="28" subjects_at_risk="288"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="287"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="20" subjects_affected="17" subjects_at_risk="288"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="287"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication (including, without limitation, slides and texts of oral or other public presentations and texts of any transmission through any electronic media) that report any results of the trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

